A new Cochrane review bolsters confidence in the safety and effectiveness of RSV vaccines for older adults and pregnant ...

Respiratory syncytial virus (RSV) prefusion vaccines reduced RSV illness in older adults. When pregnant women received RSV F protein-based vaccines, their babies had fewer serious RSV illnesses. This ...

Susan Green developed a stubborn cough in December 2023. Nearly two years after contracting respiratory syncytial virus, or ...

Respiratory syncytial virus (RSV) continues to affect infants and older and immunocompromised people around the world. These ...

A new Cochrane review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in ...

Vaccines for respiratory syncytial virus (RSV) reduce the risk of infection in older adults and infants, according to a new ...

When Laura Ehrlich gave birth to her first child in 2020, the COVID-causing virus wasn’t the only threat facing her son. Born ...

The review demonstrates that vaccines for respiratory syncytial virus (RSV) are both safe and effective in protecting groups ...

A tragic RSV vaccine trial in the 1960s set the field back for decades. Here’s how scientists finally made breakthroughs in ...

Investors were spooked by the miss, and shares in Nasdaq-listed Enanta were down around 11%, having risen sharply in ...

Enata Pharmaceuticals said it didn't meet its primary endpoint in a Phase 2b study of zelicapavir, its proposed treatment for Respiratory Syncytial Virus, or RSV, in high-risk adults.

Enanta Pharmaceuticals said its experimental respiratory syncytial virus treatment significantly quickened recovery in a mid-stage study of adults at high risk of complications from the infection. The ...